Showing 1-16 of 16 results for "A2290"
C Papadea et al.
Critical reviews in clinical laboratory sciences, 27(1), 27-58 (1989-01-01)
Human IgG consists of two identical heavy (H) chains and two identical light (L) chains joined by interchain disulfide bridges. Heterogeneity in the amino acid sequences of the H and L polypeptides results in at least three types of IgG...
A G Norden et al.
Kidney international, 60(5), 1885-1892 (2001-11-13)
Glomerular sieving coefficients (GSCs) of proteins have been measured extensively in animals but not humans. We have studied the proteinuria of Fanconi syndrome, a "knock-out" of renal tubular protein reabsorption, to estimate GSCs and detect potential contributors to development of...
Christian Loch et al.
Journal of pharmaceutical sciences, 103(2), 517-526 (2013-12-07)
Intravitreal injections and drug-loaded implants are current approaches to treat diseases of the posterior eye. To investigate the release of active agents and their distribution in the vitreous body, a new test system was developed that enables a realistic simulation...
M Bowman et al.
Journal of thrombosis and haemostasis : JTH, 11(3), 512-520 (2013-01-15)
Type 3 von Willebrand disease (VWD) is the most severe form of the disease and is classically inherited in an autosomal recessive fashion. The aim of the current study was to investigate the molecular pathogenesis of a Canadian cohort of...
Cheolho Cheong et al.
Blood, 116(19), 3828-3838 (2010-07-30)
Protein vaccines for T-cell immunity are not being prioritized because of poor immunogenicity. To overcome this hurdle, proteins are being targeted to maturing dendritic cells (DCs) within monoclonal antibodies (mAbs) to DC receptors. To extend the concept to humans, we...
F Cataldo et al.
Minerva pediatrica, 42(12), 509-514 (1990-12-01)
IgG are the most common isotype of Ig and include four subclasses which differ from one another in the following ways: their initial amino acid sequence, their physical and chemical properties and the different serum concentrations reached with age. Every...
L Le Berre et al.
Kidney international, 58(6), 2502-2511 (2000-12-15)
Patients suffering from focal and segmental glomerulosclerosis (FSGS) and in whom this disease recurs after transplantation are likely to have an active form of the disease and to have a factor(s) (such as, albuminuric factor) present in their blood that...
Junzo Nojima et al.
Clinical chemistry, 51(3), 545-552 (2005-01-08)
Venous thromboembolic events such as deep vein thrombosis and pulmonary embolism are common manifestations of antiphospholipid syndrome. Our aim was to clarify the roles of anti-phospholipid (aPL) antibodies in the pathogenesis of venous thromboembolism (VTE) in patients with systemic lupus...
M Efthymiou et al.
Thrombosis research, 170, 60-68 (2018-08-19)
Tissue factor pathway inhibitor (TFPI) antibodies, which have been reported in patients with antiphospholipid syndrome (APS), may impair TFPI activity and contribute to hypercoagulability, but their role in APS and in thrombosis remains undefined. We assessed the presence and avidity...
Koffi N'Guessan et al.
The FEBS journal, 287(18), 4068-4081 (2020-01-30)
Polymorphonuclear neutrophils contain at least four serine endopeptidases, namely neutrophil elastase (NE), proteinase 3 (PR3), cathepsin G (CatG), and NSP4, which contribute to the regulation of infection and of inflammatory processes. In physiological conditions, endogenous inhibitors including α2-macroglobulin (α2-M), serpins [α1-proteinase inhibitor (α1-PI)], monocyte...
Philippe Gatault et al.
mAbs, 7(6), 1205-1211 (2015-09-05)
The annual cost of eculizumab maintenance therapy in paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic-uremic syndrome (aHUS) exceeds $300,000 per patient. A better understanding of eculizumab pharmacokinetics and subsequent individual dose adjustment could reduce this cost. We measured the trough...
K Kiernan et al.
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 8(9), 1829-1839 (2008-08-02)
Antibodies directed at non-gal xenoantigens are responsible for acute humoral xenograft rejection when gal knockout (GalTKO) pig organs are transplanted into nonhuman primates. We generated IgM and IgG gene libraries using peripheral blood lymphocytes of rhesus monkeys initiating active xenoantibody...
Joanne L Zahorsky-Reeves et al.
BMC immunology, 7, 3-3 (2006-03-22)
The use of porcine cells and organs as a source of xenografts for human patients would vastly increase the donor pool; however, both humans and Old World primates vigorously reject pig tissues due to xenoantibodies that react with the polysaccharide...
L D Ballam et al.
Journal of clinical pathology, 53(4), 314-317 (2000-05-24)
The salivary diagnosis of Helicobacter pylori infection offers attractive possibilities for the epidemiological study of infection in children. Salivary enzyme linked immunosorbent assay (ELISA) is less reliable then serum ELISA, owing to variable transudation of immunoglobulin. In addition, children are...
David Daydé et al.
Blood, 113(16), 3765-3772 (2008-11-26)
Clinical studies have shown a large interindividual variability in rituximab exposure and its significant influence on clinical response in patients receiving similar doses of antibody. The aim of this study was to evaluate the influence of tumor burden on dose-concentration-response...
Philippe A Denoël et al.
Clinical and vaccine immunology : CVI, 14(10), 1362-1369 (2007-08-19)
It has been repeatedly observed that mixing Haemophilus influenzae type b (Hib) conjugate vaccines with acellular pertussis-containing vaccines (diphtheria-tetanus-acellular pertussis [DTPa]) resulted in a reduced magnitude of the anti-polyriboseribitolphosphate antibody response compared to that obtained when Hib vaccines were administered...

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

MilliporeSigma

Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.